Eli Lilly lifts revenue outlook as weight-loss shots offset Foundayo sales miss, shares jump
Eli Lilly raised its full-year revenue forecast to $91B-$92B, up from $85B-$87B, driven by strong demand for its weight-loss drugs Mounjaro and Zepbound. Third-quarter revenue was $24.4B, beating estimates, while adjusted profit per share also exceeded expectations. Foundayo, a newer obesity pill, underperformed but saw strong US demand. Shares rose 8% following the news.
How this was made
The 30-second read
Why it matters
The company’s raised revenue forecast and Q3 beat are immediate positives, but the Foundayo sales miss and price erosion details keep the competitive and margin debate active.
Market read
This is a same-day earnings-and-guidance catalyst for LLY, with the market balancing stronger topline outlook against a specific product ramp concern.
What to watch
The CFO attributes Foundayo shortfall to channel stocking and cites inventory effects; traders may need to watch subsequent quarters for whether demand sustains after the launch-quarter pull-forward.
Background
Lilly is competing in the GLP-1 obesity market against Novo Nordisk, with investors tracking both injectable demand (Mounjaro, Zepbound) and the oral obesity pill Foundayo ramp.
Ticker impact
Eli Lilly raised full-year revenue guidance to $91B-$92B and beat Q3 profit as weight-loss demand offset a weaker Foundayo launch.
Likely upward bias as the market reprices revenue expectations higher, partially offset by lingering concerns about Foundayo ramp.
The article reports a specific guidance increase versus prior forecast, a Q3 revenue/EPS beat, and a concrete Foundayo sales shortfall that investors are actively monitoring.
Market effects
Reinforces GLP-1 leadership narrative and may intensify read-through competition expectations across the obesity drug class.
US large-cap biotech sentiment likely supported by the same-day guidance beat.
Competitive dynamics with Novo Nordisk remain central, influencing global GLP-1 supply and pricing expectations.
Counterpoint
The Foundayo miss and realized price declines (including US price pressure tied to Zepbound) suggest margin risk could re-emerge even with higher revenue guidance.
Key entities
- companyEli Lilly
Raised full-year revenue outlook and reported Q3 beat; Foundayo sales lagged estimates.
- companyNovo Nordisk
Named as Danish rival whose first-mover edge investors compare against Lilly’s oral Foundayo.
- productFoundayo
Lilly’s newer obesity pill; Q3 sales came in below estimates and is a key ramp test.
- productMounjaro
Diabetes drug whose Q3 sales growth helped offset Foundayo weakness.
- productZepbound
Obesity injection; Q3 sales beat estimates.
